flow cytometry: 5-10 μg/test using using HeLa cells. immunoblotting: 0.5-1 μg/mL using whole extracts of HeLa cells. immunofluorescence: 4-8 μg/mL using using HeLa cells.
Monoclonal Anti-CDA (mouse IgG2a isotype) is derived from the hybridoma CDA-40 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to an internal sequence of human CDA conjugated to KLH. CDA (Cytidine deaminase) also known as cytidine aminohydrolase or CDD. The enzyme is active only as an intact tetramer, since three different monomers concur to the formation of each of the four active sites.
Immunogen
synthetic peptide corresponding to an internal sequence of human CDA .
Application
Monoclonal Anti-CDA antibody may be used in several immunochemical techniques including:
immunoblotting (~16 kDa)
flow cytometry
immunocytochemistry
Biochem/physiol Actions
Cytidine deaminase (CDA) is an intracellular enzyme of the pyrimidine salvage pathways. It catalyzes that deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively. In addition, It also catalyzes the deamination of cytosine nucleoside analogues such as ARA-C (cytosine arabinoside) and 5-AZA-CdR (5-aza-2′-deoxycytidine) used in chemotherapy, leading to the loss of their pharmacological activity. CDA inhibitors such as tetrahydrouridine (THU) are interesting therapeutically for use in combination with chemotherapy drugs in patients with leukemia, to enhance drugs activity.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Cancer chemotherapy and pharmacology, 30(1), 7-11 (1992-01-01)
Deamination of the nucleoside analogues ARA-C and 5-AZA-CdR by CR deaminase results in a loss of antileukemic activity. To prevent the inactivation of these analogues, inhibitors of CR deaminase may prove to be useful agents. In the present study we
Nucleosidic DNA demethylating epigenetic drugs--a comprehensive review from discovery to clinic
Cytidine deaminase (EC 3.5.4.5, CDA), an enzyme of the pyrimidine salvage pathways, is responsible for the degradation and inactivation of several cytidine-based antitumor drugs such as cytarabine, gemcitabine, decitabine, and azacytidine. Thus, CDA inhibitors are highly sought after as compounds to
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
